SK海力士股价波动与在华工厂许可证分析
SK海力士股价波动与在华工厂许可证分析
I'll start by verifying the SKHY quote and searching for the license news.
SKHY quote confirmed (NASDAQ, 2026-11-04 16:00 ET, -5.12%). Now I need the actual license-delay report and its context.
The early-November license-delay report hasn't surfaced yet. I'll read the primary VEU article and run one more targeted search.
The JoongAng article is dated August 2025, not 2026, and it states the key constraint: licenses for existing China fabs, but not for capacity expansion. Next I'll check for the recent license-status report and SK hynix's latest capex and China exposure.
Searches aren't converging on the early-November report. I'll check one more source on the US-side alternative, SK hynix's reported talks on US memory production.
Conclusion: The delay is probably material for SK hynix's China-site expansion, but a modest risk to group-wide capacity. I could not confirm the specific early-November report that US equipment licenses are unapproved, and I found no source linking the 5.12% drop to it. Treat the delay as an unverified premise.
Data as of: SKHY quote for the regular session ending 2026-11-04 16:00 ET (Wednesday; 2026-11-04T21:00:00Z). Policy sources are dated August 2025 to September 2026, so some may be stale.
The quote
- SKHY (NASDAQ, named SK海力士 in the quote) closed at , down from a previous close.
- The quote does not say why the stock moved. Before attributing the move to licensing, check for other news on 4 November.
- The quote names SK海力士 but does not confirm that SKHY is an ADR or share class of SK hynix. I did not verify the instrument's structure or its exposure to SK hynix's fabs.
The policy evidence
- The US Commerce Department revoked validated end-user (VEU) status for SK hynix's China plants, including Dalian. The article says Washington plans to license existing China facilities but does not intend to grant licenses to expand capacity or upgrade technology ().
- Exposure cited in that article: about 40% of SK hynix's DRAM is made in Wuxi and about 20% of its NAND in Dalian. These figures are from 2025 and need updating from SK hynix's latest filings.
- Under this framework, the expansion licenses are unlikely to be granted regardless of timing. The pending-license risk therefore mainly affects the timing of an already-restricted expansion and any upgrades or maintenance tools for existing China lines.
- A separate report says SK hynix and Samsung have been testing Chinese-made AMEC tools in their China fabs as a hedge (). This is a source-reported attempt to limit dependence, not evidence of approved capacity.
- US capacity alternatives are exploratory. Reuters reported on 16 Sep 2026 that SK hynix is in talks with Intel about producing memory in Ohio, possibly by leasing part of Intel's complex. SK hynix said "nothing has been confirmed," and Korean national-core-technology review could apply (Asia Business Daily, citing Reuters).
Materiality reasoning (my analysis, not a sourced forecast)
- Low to moderate for group output. Most capacity growth is not in China, and the source does not quantify the Korean build-out. I could not verify SK hynix's current capex guidance or capacity split.
- Higher for China-site upgrades. If pending items include tools for existing Wuxi or Dalian lines, the effect could be on output and cost, not only on new capacity. Older-node output would also face Chinese competition on price.
- Timing risk, not a base-case cut. Since expansion licenses were already signaled as unlikely, a delay mainly removes optionality and pushes out any China upgrade.
Missing information
- The specific pending license applications: which tools, which fabs, which filing dates, and whether they are expansion or maintenance.
- SK hynix's latest capex guidance, capacity by site, and China share of output, from its filings.
- Whether the Dalian and Wuxi licenses were renewed or conditioned after the 2025 revocation.
- Whether the 4 November drop had a company-specific or sector cause.
- The Ohio/Intel terms, if a deal is reached.
What to monitor
- US Commerce / BIS: license decisions, any new rule or VEU amendment, and any change to the "no expansion" stance.
- SK hynix disclosures: quarterly capex and capacity commentary, China output share, and any impairment or Dalian/Wuxi updates.
- Intel/US footprint: signing or collapse of the Ohio talks, and any Korean government review under the core-technology rules.
- China-site operations: tool installation or wafer-start announcements at Wuxi and Dalian, and any shift to domestic tools.
- Competitive pressure: Chinese memory makers' capacity and pricing, which affect whether China-site output is worth upgrading.
Sources
- Driven quote data: SKHY, NASDAQ, 2026-11-04 16:00 ET ()
- Korea JoongAng Daily, "U.S. cuts off Samsung and SK's Chinese plants from importing chipmaking tools" (dated 31 Aug 2025): https://www.koreajoongangdaily.com/business/us-cuts-off-samsung-and-sks-chinese-plants-from-importing-chipmaking-tools-it-risks-opening-market-space/11988777
- Asia Business Daily, citing Reuters (16 Sep 2026): https://www.asiae.co.kr/en/article/2026091615194803261
- Tech Insider, "Samsung, SK Hynix Test China Chip Tools After VEU Ends": https://tech-insider.org/samsung-sk-hynix-china-chip-tools-veu-2026/